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weeks for LVMi  (R2 = 0.24), body surface area for EDWT 
 (R2 = 0.32), and weight for ESWT  (R2 = 0.29). After multi-
variable analysis, cardiac biomarkers remained the strong-
est predictors of LVMi, LVEDVi and LVESVi. NT-proBNP 
but none of the acute cardiac injury biomarkers were asso-
ciated with remote LV wall thickness. Our analyses illus-
trate the value of cardiac specific biochemical biomark-
ers in predicting global LV remodeling after STEMI. We 
found no evidence for a hypertrophic response of the non-
infarcted myocardium.
Keywords Magnetic resonance imaging · Myocardial 
infarction · Left ventricular remodeling · Multivariable 
analysis
Introduction
Myocardial injury caused by ST-elevation myocardial 
infarction (STEMI) leads to left ventricular (LV) remod-
eling, resulting in functional and structural LV changes [1]. 
Over time, remodeling adversely affects cardiac function 
and can lead to significant morbidity and mortality [2]. To 
attenuate LV remodeling, early risk stratification is needed 
to allow monitoring and more aggressive treatment of high-
risk patients.
The most widely investigated functional LV characteris-
tic to predict patient outcome after STEMI is LV ejection 
fraction (LVEF) [3]. Several structural LV characteristics 
have also shown to be important predictors of cardiovas-
cular adverse events and death, including LV end diastolic 
volume (LVEDV), end systolic volume (LVESV) and mass 
(LVM) [4–8]. Cardiovascular magnetic resonance (CMR) 
imaging is the current reference standard for assessing ven-
tricular volumes and mass [9]. There is limited knowledge 
Abstract Adverse left ventricular (LV) remodeling after 
acute ST-elevation myocardial infarction (STEMI) is asso-
ciated with morbidity and mortality. We studied clinical, 
biochemical and angiographic determinants of LV end 
diastolic volume index (LVEDVi), end systolic volume 
index (LVESVi) and mass index (LVMi) as global LV 
remodeling parameters 4 months after STEMI, as well as 
end diastolic wall thickness (EDWT) and end systolic wall 
thickness (ESWT) of the non-infarcted myocardium, as 
compensatory remote LV remodeling parameters. Data was 
collected in 271 patients participating in the GIPS-III trial, 
presenting with a first STEMI. Laboratory measures were 
collected at baseline, 2 weeks, and 6–8 weeks. Cardiovas-
cular magnetic resonance imaging (CMR) was performed 4 
months after STEMI. Linear regression analyses were per-
formed to determine predictors. At baseline, patients were 
21% female, median age was 58 years. At 4 months, mean 
LV ejection fraction (LVEF) was 54 ± 9%, mean infarct size 
was 9.0 ± 7.9% of LVM. Strongest univariate predictors (all 
p < 0.001) were peak Troponin T for LVEDVi  (R2 = 0.26), 
peak CK-MB for LVESVi  (R2 = 0.41), NT-proBNP at 2 
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of the predictive value of clinical, biochemical and angio-
graphic factors for LVM, LVEDV or LVESV after STEMI. 
The compensatory hypertrophic response of the remote 
non-infarcted myocardium (end diastolic wall thickness 
(EDWT) and end systolic wall thickness (ESWT)) might 
also play an important role in the remodeling after myocar-
dial infarction but this has not been studied in humans.
The objective of this study is to increase our under-
standing of the determinants of LV structural remodeling 
after STEMI. We performed a retrospective analysis of the 
GIPS-III trial, in which CMR was performed 4 months 
after STEMI. The primary endpoint of the GIPS-III trial 
on LVEF has been published previously [10]. We studied 
the clinical, biochemical and angiographic determinants 
of LVEDV, LVESV and LVM indexed to body surface 
area (BSA), as global LV remodeling parameters, as well 
as EDWT and ESWT of the non-infarcted myocardium, as 
compensatory remote LV remodeling parameters.
Materials and methods
Study population and procedures
Data was used from all patients included in the GIPS-III 
trial who underwent CMR assessment. The GIPS-III trial 
was a single-center, randomized, placebo-controlled trial, 
including STEMI patients treated with percutaneous coro-
nary intervention (PCI) at the University Medical Center 
Groningen between January 1, 2011 and May 26, 2013, pre-
viously described in more detail [10, 11]. Patients (N = 380) 
without known diabetes mellitus or previous myocardial 
infarction were randomized to take either placebo or a dos-
age of 500 mg metformin twice daily during a period of 4 
months, in addition to standard protocolized care accord-
ing to ESC guidelines [12]. The primary objective was to 
assess the effect of metformin on cardiac systolic function 
(LVEF), as measured with CMR at 4 months after STEMI. 
Major exclusion criteria were contraindications for CMR, 
the need for coronary artery bypass graft surgery, previous 
myocardial infarction, known diabetes, and severe renal 
dysfunction. Informed consent was obtained from all indi-
vidual participants. All significant bystander lesions were 
treated by PCI before CMR assessment. In total, 271 CMR 
assessments were analyzed in a core laboratory.
Cardiovascular magnetic resonance imaging
Cardiovascular magnetic resonance imaging (CMR) was 
performed 4 months after STEMI. LVEDV, LVESV, LVM, 
EDWT and ESWT were measured in addition to infarct 
size and LVEF, the primary outcome measure of the 
GIPS-III study [13]. Imaging was performed on a 3.0  T 
whole-body MRI scanner (Achieva; Philips) using a phased 
array cardiac receiver coil. During repeated breath holds, 
electrocardiogram-gated steady state free precession cine 
images were acquired in contiguous short-axis slices of 
1  cm covering the entire LV. Endocardial and epicardial 
borders were outlined in the end systolic and end diastolic 
images. LVESV, LVEDV and LVM were calculated using 
the summation of slice method; LVM was measured at end-
diastole. ESWT, EDWT and fraction of hyper-enhancement 
as measured with late gadolinium enhancement (LGE) 
were determined for each myocardial segment in a 16-seg-
ment model, based on the standard 17-segment model 
without the apical (17th) segment [14]. Infarct size was 
determined by summation of the volume of hyper-enhance-
ment per slice, and expressed as percentage of total LVM. 
EDWT and ESWT of remote non-infarcted myocardium 
was defined as the mean EDWT and ESWT of all myocar-
dial segments without LGE hyperenhancement. LVEDV, 
LVESV and LVM were indexed (i) to body surface area 
(BSA) according to the DuBois method [15]. Weight 
measurements at 4 months were used for indexation. An 
independent core laboratory (Image Analysis Center, VU 
University Medical Center, Amsterdam, the Netherlands) 
assessed the CMR scans, blinded for patient data.
Laboratory analysis
Laboratory analysis was performed at the laboratory 
department of the University Medical Center Groningen. 
Blood samples for assessment of myocardial injury with 
creatine kinase (CK), myocardial band of CK (CK-MB), 
and Troponin T were collected according to study protocol 
at baseline, and at 3, 6, 9, 12, 18, 24, and 36 h after PCI. 
Using the trapezoid method, area under the curve (AUC) 
values were determined over the first 36 h post-PCI from 
a median of seven blood samples [16]. Other biochemi-
cal measures collected at baseline, at 2 weeks and at 6–8 
weeks included N-terminal pro brain natriuretic peptide 
(NT-proBNP), glucose and estimated glomerular filtration 
rate (eGFR) as determined by the CKD-EPI formula [17].
Statistical analysis
Pearson product-moment correlation coefficient (Pear-
son’s rho) was derived to assess correlation between infarct 
size and the investigated structural LV characteristics. The 
percentage of deviating values of LVMi, LVEDVi and 
LVESVi was derived by comparison with 95th percentile 
(P95) values in a healthy reference population [18]. Uni-
variate and multivariable analyses were performed using 
linear regression. Results from univariariate analyses were 
presented with standardized beta (Std. β) and significance 
level (p-value). Age, sex and variables with p-value ≤0.10 
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after correction for age and sex (and BSA in EDWT and 
ESWT), were included in multivariable analysis. Collinear 
variables were removed from multivariable analysis, based 
on the lowest  R2 when combined with age and sex, until 
variance inflation factors were lower than ten. Multivari-
able linear regression analyses were performed using a for-
ward stepwise algorithm, with cutoff for entry set at a sig-
nificance level 0.05 to find independent predictors of LVMi, 
LVEDVi, LVESVi, EDWT and ESWT. To validate the 
models within the study cohort, a backward stepwise algo-
rithm was used with cutoff for removal set at significance 
level 0.10, and significance level set at 0.05. Additionally, 
the bootstrap method was utilized, using 1000 repetitions 
for model selection, and the order of most prevalent vari-
ables was compared with the previous models. Significant 
variables in the multivariable model were reported with 
Std. β and p-value. The coefficient of determination  (R2) 
was derived to assess the proportion of variance predicted 
by the multivariable linear regression model. Variables 
within the models were tested for significant interactions, 
in conjunction with age and sex. Analyses were performed 




Cardiovascular magnetic resonance imaging (CMR) data 
was available for 271 (71%) patients participating in the 
GIPS-III trial. Baseline and follow-up clinical, biochemi-
cal, and angiographic characteristics are presented in 
Table 1.
LV structural characteristics
Left ventricular (LV) structural characteristics in the study 
population are presented in addition to reference values of 
healthy adults of comparable age (Table 2) [18]. LVESVi 
shows most deviations from reference values, followed by 
LVEDVi, and LVMi. LVESVi has the strongest correla-
tion with infarct size as measured by CMR, followed by 
LVEDVi, and LVMi. EDWT and ESWT have no signifi-
cant correlation with CMR determined infarct size.
Univariate analysis
Univariate linear regression results are presented in 
Tables 3 and 4. Randomization to metformin compared to 
placebo treatment had no effect on structural LV character-
istics. Peak and AUC values for CK, CK-MB and Troponin 
T were significant predictors of LVEDVi, LVESVi and 
Table 1  Baseline and follow-up clinical, angiographic and biochemi-
cal characteristics
IQR interquartile range, PCI percutaneous coronary intervention, 
LAD left anterior descending artery, LCX left circumflex artery, RCA 
right coronary artery, TIMI thrombolysis in myocardial infarction, CK 
creatine kinase, AUC area under the curve, NT-proBNP N-terminal 
pro brain natriuretic peptide, eGFR estimated glomerular filtration 
rate, HbA1c glycated hemoglobin
Characteristics Median (IQR) or n 
(%), n = 271
Age, years 58 (49–66)
Sex, % female 58 (21.4)
Body mass index, kg/m² 26.6 (24.4–29.4)
Weight, kg 83 (75–95)
Height, cm 178 (170–184)
Race/ethnicity, % Caucasian 257 (94.8)
Hypertension, % 75 (27.7)
Dyslipidemia, % 168 (62.0)
Current smoking, % 139 (51.3)
Stroke, % 1 (0.4)
Previous PCI, % 4 (1.5)
Systolic blood pressure, mmHg 132 (119–146)
Diastolic blood pressure, mmHg 83 (74–95)
Heart rate, beats/min 74 (64–84)
Ischemia time, min 155 (105–240)










Infarct-related artery TIMI flow post-PCI, %
 2 17 (6.3)
 3 254 (93.7)





Peak CK-MB, U/L 163 (76–328)
AUC CK-MB, U/L s 10−8 0.103 (0.044–1.86)
Peak CK, U/L 1420 (680–3110)
AUC CK, U/L s 10−8 1.02 (0.45–2.16)
Peak Troponin T, ng/L 49 (22–146)
AUC Troponin T, ng/L s 10−5 1.35 (0.48–2.65)
NT-proBNP, ng/L 80 (38–188)
NT-proBNP at 2 weeks, ng/L 555 (212–1150)
NT-proBNP at 6–8 weeks, ng/L 287 (126–631)
eGFR, mL/min 96 (86–103)
Glucose, mmol/L 8.2 (6.9–9.5)
HbA1c, % 5.8 (5.6–6.0)
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LVMi, but apart from AUC of Troponin T, did not signifi-
cantly predict EDWT and ESWT. Strongest univariate pre-
dictors were peak Troponin T for LVEDVi, peak CK-MB 
for LVESVi, NT-proBNP at 2 weeks for LVMi, BSA for 
EDWT, and weight for ESWT.
Multivariable analysis
Multivariable linear regression models of LVEDVi, 
LVESVi, LVMi, EDWT and ESWT are presented in 
Table  5. Forward and backward models were identical. 
Bootstrap models were identical, except the model for 
LVMi, which also included AUC Troponin T in the five 
most frequently selected variables, EDWT, which also 
included culprit in the right coronary artery (RCA) in the 
ten most frequently selected variables, and ESWT, which 
also included heart rate at admission in the nine most fre-
quently selected variables. In the multivariable model for 
LVESVi, significant interactions were found for age with 
peak Troponin T and age with NT-proBNP at 5 months. 
Adding the interaction term between age and peak Tro-
ponin T increased the explained variance from 58 to 59%. 
In the multivariable model for LVEDVi, a significant inter-
action was found for age with sex, increasing explained 
variance from 49 to 50%. In the multivariable model for 
LVMi, significant interactions were found for NT-proBNP 
at 2 weeks with sex and hypertension at baseline. Adding 
the interaction term between NT-proBNP at 2 weeks and 
hypertension to the model increased the explained variance 
from 43 to 45%. In the multivariable model for EDWT, sig-
nificant interactions were found for NT-proBNP at 2 weeks 
with sex, hypertension, heart rate and HbA1c. Adding 
Table 2  LV structural 
characteristics measured with 
CMR at 4 months
LV left ventricle, CMR cardiovascular magnetic resonance imaging, SD standard deviation, P95 95th per-
centile, P5 5th percentile, SD standard deviation, LVMi left ventricular mass index, LVEDVi left ventricular 
end diastolic volume index, LVESVi left ventricular end systolic volume index, EDWT end diastolic wall 
thickness, ESWT end systolic wall thickness, LVEF left ventricle ejection fraction
Study cohort n = 271 CMR 
parameter
(mean ± SD) Correlation with infarct 
size (Pearson’s rho)
p % above P95 
or below P5
LVMi (g/m2) 50.4 ± 10.7 0.26 <0.001 17.2
LVEDVi (mL/m2) 96.1 ± 20.2 0.55 <0.001 46.4
LVESVi (mL/m2) 45.3 ± 17.1 0.70 <0.001 82.4
EDWT (mm) 5.91 ± 0.85 – 0.94 –
ESWT (mm) 9.36 ± 1.34 – 0.36 –
LVEF (%) 53.9 ± 8.5 −0.72 <0.001 79.4
Infarct size (% LVM) 9.0 ± 7.9 – – 87.8
Table 3  Univariate regression 
analysis of LV structural 
characteristics with clinical 
parameters
LV left ventricle, β standardized beta, LVEDVi left ventricular end diastolic volume index, LVESVi left ven-
tricular end systolic volume index, LVMi left ventricular mass index, EDWT end diastolic wall thickness, 
ESWT end systolic wall thickness
Factor LVEDVi LVESVi LVMi EDWT ESWT
β p β p β p β p β p
Age −0.14 0.02 −0.06 0.29 0.00 0.96 0.12 0.052 0.12 0.053
Female sex −0.13 0.03 −0.10 0.11 −0.24 <0.001 −0.28 <0.001 −0.23 <0.001
Body surface area 0.08 0.17 0.04 0.46 0.11 0.07 0.32 <0.001 0.28 <0.001
Weight 0.08 0.18 0.02 0.69 0.09 0.13 0.29 <0.001 0.29 <0.001
Height 0.12 0.047 0.08 0.17 0.17 0.005 0.26 <0.001 0.24 <0.001
Hypertension −0.01 0.87 −0.01 0.82 0.13 0.04 0.20 0.002 0.14 0.03
Dyslipidemia 0.07 0.27 0.10 0.11 −0.04 0.47 −0.03 0.61 −0.05 0.40
Current smoking −0.04 0.47 −0.03 0.58 0.04 0.49 0.04 0.51 0.04 0.53
Previous PCI 0.02 0.72 0.02 0.70 0.01 0.83 0.06 0.33 0.05 0.44
Systolic blood pressure 0.06 0.32 0.02 0.68 0.16 0.011 0.21 0.001 0.23 <0.001
Diastolic blood pressure 0.13 0.03 0.10 0.095 0.21 <0.001 0.19 0.003 0.23 <0.001
Heart rate 0.01 0.88 0.06 0.34 0.13 0.03 0.21 0.001 0.18 0.004
Ischemia time 0.00 0.97 0.04 0.50 0.04 0.56 −0.02 0.71 −0.01 0.89
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the interaction term between NT-proBNP at 2 weeks and 
HbA1c increased the explained variance from 45 to 47% 
and dropped NT-proBNP at baseline out of the model. In 
the multivariable model for ESWT, significant interac-
tions were found for NT-proBNP at 2 weeks with sex and 
HbA1c. Adding the interaction between NT-proBNP and 
HbA1c increased the explained variance from 35 to 37%, 
and dropped NT-proBNP at baseline, sex and current 
smoking out of the model.
Delta values for NT-proBNP and eGFR between base-
line and follow-up measures were tested in multivariable 
analysis but were not of additional value. Receiver operat-
ing characteristic (ROC) curves were made to analyze and 
visualize the performance of the multivariable models com-
pared with the strongest univariate predictors in predicting 
LVEDVi, LVESVi and LVMi to be above P95 reference 
values (Fig. 1). In addition, a ROC curve was constructed 
for predicting deviations in LVEF, using peak CK-MB and 
the multivariable model described earlier [19]. The multi-
variable models for LVEDVi and LVMi had a significantly 
higher area under the ROC curve compared to the strongest 
univariate predictors (p = 0.004 and p < 0.001 respectively), 
the area under the ROC curve for LVESVi and LVEF did 
not improve (p = 0.11 and 0.29 respectively).
Discussion
We studied the clinical, biochemical and angiographic pre-
dictors of LV remodeling characteristics 4 months after 
STEMI. Commonly used cardiac specific biomarkers for 
cardiac injury were the strongest predictors of the global 
structural LV remodeling response. We also considered 
the compensatory response of the remote non-infarcted 
LV wall thickness to STEMI. Interestingly, LV wall thick-
ness of non-infarcted myocardium was not correlated with 
infarct size, biomarkers for cardiac injury, or other LV 
Table 4  Univariate regression analysis of LV structural characteristics with angiographic and biochemical parameters
LV left ventricle, β standardized beta, LVEDVi left ventricular end diastolic volume index, LVESVi left ventricular end systolic volume index, 
LVMi left ventricular mass index, EDWT end diastolic wall thickness, ESWT end systolic wall thickness, PCI percutaneous coronary interven-
tion, LCX left circumflex artery, RCA right coronary artery, TIMI thrombolysis in myocardial infarction, CK creatine kinase, AUC area under the 
curve, NT-proBNP N-terminal pro brain natriuretic peptide, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin
Factor LVEDVi LVESVi LVMi EDWT ESWT
β p β p β p β p β p
Single vessel disease 0.00 0.97 −0.03 0.60 −0.03 0.67 0.01 0.89 0.01 0.89
Infarct-related artery 0.02 <0.001 0.06 0.003 0.26
 LCX −0.01 0.93 0.00 0.95 0.00 0.95 −0.10 0.15 −0.10 0.17
 RCA −0.17 0.01 −0.23 <0.001 −0.15 0.03 −0.23 0.001 −0.10 0.17
Infarct-related TIMI flow pre-PCI <0.001 <0.001 0.02 0.33 0.57
 TIMI 1 −0.02 0.74 −0.02 0.77 0.09 0.15 0.11 0.08 0.07 0.30
 TIMI 2 −0.19 0.002 −0.19 0.002 −0.06 0.37 0.03 0.60 0.00 0.93
 TIMI 3 −0.28 <0.001 −0.25 <0.001 −0.15 0.02 −0.01 0.86 −0.05 0.43
Infarct-related TIMI 3 post-PCI −0.08 0.18 −0.09 0.12 −0.02 0.74 0.02 0.75 −0.03 0.60
Myocardial blush grade 0.08 0.03 0.31 0.99 0.70
 MBG 1 0.08 0.52 0.08 0.52 0.05 0.72 −0.02 0.87 −0.13 0.32
 MBG 2 −0.11 0.55 −0.09 0.64 −0.13 0.50 −0.04 0.84 −0.23 0.24
 MBG 3 −0.13 0.52 −0.17 0.41 −0.09 0.66 −0.06 0.79 −0.22 0.29
Peak CK-MB 0.50 <0.001 0.64 <0.001 0.24 <0.001 0.07 0.25 −0.01 0.90
AUC CK-MB 0.49 <0.001 0.62 <0.001 0.26 <0.001 0.10 0.12 0.02 0.70
Peak CK 0.51 <0.001 0.64 <0.001 0.24 <0.001 0.07 0.14 0.00 0.97
AUC CK 0.51 <0.001 0.62 <0.001 0.26 <0.001 0.10 0.24 0.02 0.81
Peak Troponin T 0.51 <0.001 0.64 <0.001 0.27 <0.001 0.10 0.11 0.02 0.76
AUC Troponin T 0.51 <0.001 0.62 <0.001 0.32 <0.001 0.15 0.02 0.08 0.23
NT-proBNP 0.24 <0.001 0.23 <0.001 0.13 <0.001 0.20 0.001 0.20 0.002
NT-proBNP at 2 weeks 0.42 <0.001 0.49 <0.001 0.24 <0.001 0.27 <0.001 0.20 0.002
NT-proBNP at 6–8 weeks 0.51 <0.001 0.61 <0.001 0.19 <0.001 0.27 <0.001 0.18 0.007
eGFR 0.15 0.014 0.10 0.11 −0.01 0.89 −0.12 0.06 −0.10 0.10
Glucose 0.14 0.02 0.14 0.03 0.11 0.08 0.11 0.095 0.11 0.09
HbA1c −0.08 0.21 −0.08 0.17 0.06 0.29 0.18 0.004 0.19 0.002
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remodeling parameters, suggesting that the presumed com-
pensatory response of remote myocardium is not related to 
cardiac injury caused by STEMI.
Global remodeling
Left ventricular (LV) volume indices after STEMI are 
affected by adverse remodeling, as emphasized by the 
strong correlations with infarct size. Predictors of LV 
dilatation after STEMI in previous studies include infarct 
zone, wall motion score index, peak CK, extent of coro-
nary artery disease, LV dyssynchrony, and early mitral 
regurgitation [7, 20, 21]. In daily clinical practice, physi-
cians generally rely on enzymatic infarct size to predict LV 
remodeling. Our data suggests that NT-proBNP after 6–8 
weeks is a better predictor of LV volume indices compared 
to (peak or AUC) Troponin T, CK, and CK-MB, and could 
be used more frequently in clinical practice for risk stratifi-
cation and treatment optimization. Reference values for LV 
volume indices depend on age and sex, as reflected in both 
multivariable models [18, 22].
Within the multivariable model for LVEDVi, NT-
proBNP was the strongest predictor, probably due to the 
relationship between LVEDV, wall stress and NT-proBNP. 
Heart rate during CMR assessment was an independent 
predictor of LVEDVi, which is a physiological effect result-
ing from increased LV filling times at lower heart rates.
LVESVi increases and LVEF declines in post-infarction 
LV remodeling [1]. In contrast with LVEDVi, the strongest 
predictor in the multivariable model for LVESVi was peak 
CK, emphasizing the strong relationship between infarct 
size and systolic function. Out of all remodeling parame-
ters, LVESVi showed most deviations from reference val-
ues. The multivariable model had the highest explained 
variance and was comprised of biochemical biomarkers 
only.
LVMi was most strongly predicted by NT-proBNP, 
which was the only biochemical biomarker to remain sig-
nificant in multivariable regression analysis adjusted for 
age, sex, hypertension, and blood pressure. NT-proBNP has 
been previously associated with LVM, and has been sug-
gested to be used as a screening tool for LV hypertrophy 
[23–25]. NT-proBNP at 2 weeks predicts LVMi more accu-
rately compared with levels at other time points suggest-
ing, as might be expected, that NT-proBNP levels in the 
acute phase of STEMI are not representative. The predic-
tive value of blood pressure for LVMi has been previously 
reported in healthy cohorts but is also a predictor at hospi-
tal admission for STEMI [26].
Previous studies in humans have shown that LVMi is 
reduced in the first months after infarction due to the loss 
of infarcted myocardium, although baseline measurements 
were always acquired after STEMI [27, 28]. We found a 
significant positive correlation of LVMi with infarct size 
as measured with CMR after 4 months. This could indicate 
that patients with LV hypertrophy develop a larger infarct 
size, which has been suggested before [29]. Alternatively, 
Table 5  Multivariable regression analysis of LV structural character-
istics
LV left ventricle, R² coefficient of determination, Std. β standardized 
beta, P95 95th percentile of reference value, LVMi left ventricular 
mass index, EDWT end diastolic wall thickness, ESWT end systolic 
wall thickness, LVEDVi left ventricular end diastolic volume index, 
LVESVi left ventricular end systolic volume index, NT-proBNP N-ter-
minal pro brain natriuretic peptide, HbA1c glycated hemoglobin, 
TIMI thrombolysis in myocardial infarction, AUC area under the 
curve, CK creatine kinase, eGFR estimated glomerular filtration rate
Std. β p-value
LVEDVi  (R2 = 0.49)
 Age −0.30 <0.001
 Female sex −0.16 0.001
 Heart rate during CMR −0.19 <0.001
 AUC Troponin T 0.28 <0.001
 NT-proBNP at 6–8 weeks 0.47 <0.001
LVESVi  (R2 = 0.58)
 Age −0.22 <0.001
 Female sex −0.14 0.001
 Peak Troponin T 0.42 <0.001
 NT-proBNP at 6–8 weeks 0.45 <0.001
LVMi  (R2 = 0.43)
 Age −0.16 0.002
 Female sex −0.38 <0.001
 Hypertension at baseline 0.16 0.008
 Systolic blood pressure 0.16 0.003
 NT-proBNP at 2 weeks 0.58 <0.001
EDWT  (R2 = 0.45)
 Age 0.15 0.022
 Female sex −0.22 <0.001
 Body surface area 0.41 <0.001
 Heart rate at baseline 0.14 0.007
 Heart rate during CMR 0.12 0.028
 Hypertension in medical history 0.19 0.001
 Current smoking 0.13 0.019
 NT-proBNP at baseline 0.12 0.036
 NT-proBNP at 2 weeks 0.32 <0.001
 HbA1C 0.14 0.008
ESWT  (R2 = 0.35)
 Age 0.21 <0.001
 Female sex −0.18 0.016
 Body surface area 0.33 <0.001
 Heart rate during CMR 0.14 0.011
 Diastolic blood pressure 0.19 0.001
 Current smoking 0.13 0.037
 NT-proBNP at baseline 0.14 0.034
 NT-proBNP at 2 weeks 0.21 0.002
 HbA1c 0.16 0.006
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a compensatory hypertrophic response of the remaining, 
non-infarcted myocardium, as observed in previous animal 
studies, could explain the correlation between LVMi and 
infarct size [30, 31]. Biochemical biomarkers for myocar-
dial injury were associated with LVMi, although this was 
not significant anymore after adjusting for NT-proBNP.
Remote remodeling
We observed that predictors of LV wall thickness in the 
remote myocardium generally correspond with predic-
tors of LVMi. In addition, HbA1c appeared an inde-
pendent predictor of both increased EDWT and ESWT. 
In the GIPS-III trial, patients with known diabetes were 
excluded, but one out of six patients were diagnosed 
with diabetes after randomization [11]. In a previous 
study, patients with diabetes had higher LVMi, associated 
with an increased risk to develop HF after myocardial 
infarction [32]. This might be the result of a lower LV 
compliance. It remains speculative whether patients with 
high HbA1c levels had a higher pre-existing wall thick-
ness or if this developed after STEMI. We also found that 
active smoking at baseline is an independent predictor 
of increased wall thickness, which has been described 
before in large cohorts [33].
A previous study reports patients after STEMI to have 
significantly higher wall thickness in non-infarcted myo-
cardium, compared to control patients [27]. However, this 
was not adjusted for potential confounders such as hyper-
tension. In our study, we found no correlation between 
infarct size and remote LV wall thickness. Also, levels 
of biochemical biomarkers for myocardial injury did not 
predict remote LV wall thickness, suggesting there might 
not be a compensatory hypertrophic response of remote 
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Fig. 1  ROC curves of strongest univariate predictor and multivari-
able model predicting deviations from P95 reference values. LVEDVi 
left ventricular end diastolic volume index, LVESVi left ventricular 
end systolic volume index, LVMi left ventricular mass index, ROC 
receiver operating characteristic, NT-proBNP N-terminal pro brain 
natriuretic peptide, HbA1c glycated hemoglobin, TIMI Thromboly-
sis in Myocardial Infarction, AUC area under the curve, CK creatine 
kinase, eGFR estimated glomerular filtration rate, CK creatine kinase, 
NT-proBNP N-terminal pro brain natriuretic peptide
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Limitations
There were several limitations to our study. We did not 
determine measures of myocardial edema, which might 
have influenced the relation of remote wall thickness with 
infarct size, and did not perform stress perfusion imag-
ing to assess residual ischemia. CMR was performed 
at 4 months after STEMI, when LV remodeling might 
be ongoing. No additional CMR assessment was per-
formed prior to, or after 4 months, to assess progression 
in remodeling. Mean infarct size (9% of LV mass) in our 
cohort was relatively small compared to other STEMI 
studies, possibly due to the inclusion criteria (first 
STEMI) and efficient management (median 155  min to 
treatment). Additional studies with a larger variability in 
infarct size might help to further investigate the relation-
ship between remote myocardial remodeling after infarc-
tion. The use of in- and exclusion criteria of the GIPS-
III trial has possibly affected our results. For example, 
known diabetes was an exclusion criteria and therefore 
the effect of prevalent diabetes on LV remodeling could 
not be studied.
Conclusion
Our data underlines the strength of cardiac specific bio-
markers in predicting global LV remodeling after STEMI. 
We found no evidence for the presumed hypertrophic 
response of remote non-infarcted myocardium at 4 months 
after STEMI.
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